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RETROSPECTIVE COMPARISON OF ALLOGENEIC STEM CELL TRANS- 
PLANTATION (SCT) IN PEDIATRIC PATIENTS UTILIZING PERIPHERAL 
BLOOD STEM CELLS (PBSC) VS BONE MARROW (BM) 
D,ev,'t, R.E.; Jacobso/31z, D.; K!et~d, M. Hemato/ogy-O,colog),-Tl'a,s- 
plmzt, ClaildreT~ '.rMemorial Hospital, C,~icago, IL. 
G-CSF mobilized PBSC are increasingly used as a source of 
helnatopoietic stem cells (HSC) for allogeneic SCT. Randomized 
studies in adults uggest benefits using PBSC related to early engraft- 
ment, reduced acute to ,  city and lack of increase in acute graft-vs- 
host disease (GVIID) despite the increase in T-cell dose adminis- 
tered with PBSC. Reports comparing chronic GVHD following 
SCT using PBSC vs BM have varied. Pediatl'ic (vs adult) recipients 
of allogeneic SCT have lower rates of acute and chronic GVHD, as 
well as reduced risk for acute to,city. We report a retrospective 
comparison of 76 pediau'ic patients with hematologic malignancies, 
15 received allogeneic PBSC from matched related (n= 11) or unre- 
lated donors CURD, n= 4) fl'om 3/2000 through 9/2002.61 received 
BM from matched related (n= 5i) or URD (n= 10) from 6/I992 
through 7/2002. PBSC donors received G CSF (10 mcg/kg/d x 4d) 
for tISC mobilization. Cytoreduction therapy for all patients was 
fracdonated total body irradiation (150 cGy x8 = 1200 cGy) + etopo- 
side (1000 rag/m2 xl) + cyclophosphamide (60 mg/kg x3). Growth 
factor support with G-CSF was routinely administered beginning on 
day +7. GVHD prophylaxis was similarly uniform (Cyclosporine A 
and reduced medaotrexate-days 1, 3 & 6). All URD recipients also 
received ATG (20 mg/kg x4 post SCT) and 11 URD recipients 
received tacrolimus substituted for Cyclosporine A. Patients treated 
with other cytoreducdon protocols or alternative GVHD prophylax- 
is regimens were excluded. Although retrospective, non-randomized 
and longer follow-up exists for the BM recipients, this analysis of 
PBSC vs BM in Pediatric allogeneic SCT recipients suggests results 
similar to larger andomized studies in adults-reduced I00 day mor 
talky without increased acute GVHD. Despite shorter follow-up, 
chronic GVHD was significantly greater in PBSC recipients. Longer 
follow-up is required to better assess true rates of recurrence and 
chronic GVHD after SCT with PBSC. A randomized trial will 
require multi-center participation. Allogeneic SCT using PBSC in 
pediatric patients appears to be an acccptable alternative toBM. 
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OUTCOME OF PEDIATRIC PATIENTS WHO UNDERGO HEMATOPOITIC 
STEM CELL TRANSPLANTATION (HSCT) FOR MONOSOMY 7 AND 
OTHER CYTIOGENETICALLY ABNORMAL MYELODYSPLASTIC SYN- 
DROMES (MDS) OR ACUTE NON-LYMPHOBLASTIC LEUKEMIA (ANLL) 
A SINGLE INSTITUTION EXPERIENCE 
Kh'tzel, ~i.; Jacobsoh~z, D.; D,e'l'st, R. C'hildveJzs l~leT, oHal Hospital, 
673icago, IL. 
From March 1992 to September 2002 sixteen patients were 
diagnosed with cytogenetical]y abnormal MDS/ANLL. Our 
objective is to report the outcome of these patients after they 
received an HSCT. Of the 16 patients, there 9 males and 7 
females. Mean age at diagnosis is 7.3 years, median 6.6 (1.0-16.6), 
Race Caucasian (n=9), Afi'ican ganerican (n=2), tlispanic (n=4) and 
1 other. Type of HSCT Unrelated umbilical cord (n=8), matched 
sibling (n-3), matched unrelated (n=4) and autologous with 4-HC 
purged marrow (n=l). Eleven patients had the diagnosis of MDS 
and 5 ANLL; 8 were primary and 8 were seconda, T. The cytoge- 
netic abnormalities include: Monosomy 7 (n=10), Monosomy 5 
(n=l), Monosomy 5, 7 (n=l) Trisomy 8 (n=l), t (6-9) (n=2) and t 
(8-16) (n=1). Ablation was TBI 150cGy BID x 8 doses, VP-16 
(VP) 1000mg/m2/day xl day and Cycophosphamide (Cy) 60 
mg/kg/day x 3 days (n=9); Busulfan (Bid) hng/kg/dose x 16 doses, 
VP, Cy (n=5); and Fludarabine 25mg/m2/day x 6 days, BU 
lmg/kg/dose x 8 and ATG 40mg/kg/day x 5 clays n=(2). Cell 
doses infused MNC x 108/kg mean 0.3 (median 0.5, range 0.1- 
7.1) CD34+ cells x i06/kg mean 0.6, (median 1.8, range 0.3-16.2) 
GVHD prophylaxis included: CSA/MTX/ATG (n=10), 
CSA/MTX (n=3), CSA (n=2), none (n=l). The time to ANC>500 
was mean 31days (median 22.5days), to platelets of >20.0 mean 
36.5 days (median 37days) and platelets >50.0 mean 55 days 
(median 53 days). Grade I/ i i  GVHD develop in (n=7) Grade 
III/IV (n=2), no GVHD (n=7). No chronic GVHD (n=13), Limit 
ed (n=i) Extensive (n=l) unknown (n=l). Other complications 
included: Interstitial pneumonia (n=l) Toxic Epidermolysis (n=l) 
Fungai Infection (n=2) Hemorragic Cystitis (n=2). The Event free 
survival at 4 years post transplant is 55% (95% CI 0.4-.07). 
HSCT for patients with MDS/ANLL with cytogenetic abnormal- 
ities can be an effective treatment, even when alternative donor 
sources are used. 
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NSI AND NS2 SUBPOPULATIONS OF BONE MARROW NATURAL SUP- 
PRESSOR CELLS 
Belyaev, N.; Bogd, nmv, ,4.; Savv,lidi, P.; Zaki~ya, ova, G.: TMdieva, 
R. f ,  stitute qf l~loleczdat" Biology mid Bioche'mist/3~, Atmaty, IGtzakhsta,. 
Natural suppressor (NS) cells are hcterogenic population of 
early bone marrow haelnopoietic precm'sors that play an impor- 
tant role in chronic GVHD and also in suppression ofNK activi- 
ty during tumor development. Proceeding on numerous litera- 
tm'e data we have suggested that there are at least two NS 
subpopulations: NS1 and NS2 which are stimulated with IL-2 
and IFNg or IL-3 and GM-CSF respectively. In this work we 
have tried to prove the existence of these two NS subpopulations. 
The bone marrow cells (BMC) of CBA mice were cultivated in 
concentration of 2x106/ml under standard cell culture conditions 
for 48 h. NS activity was judged on the ability of BMC culture 
supernatants to inhibit myeloma cell proliferation by MT~F-test. 
We determined NS activity induced with IL-2 (NS1), IL-3 
(NS2) or spontaneous ( NS). NK activity of mononuclear spleen 
cells was estimated by eytoto~c assay. TGFb was determined by 
ELISA. We have shown that sNS activity- was not obselwed while 
NS1 and NS2 activity was determined and apparendy it was con- 
nected with TGFb; production because of antiproliferative activi- 
ty of supernatants corelated with TGFb concentration. Further- 
more these supernatants inhibited NK activity for certain. Earlier 
we have shown that the most sNS activity is revealed in BMC 
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